INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 171 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2018 | $393,000 | +24.0% | 3,901 | +55.7% | 0.53% | +78.8% |
Q3 2018 | $317,000 | -24.7% | 2,506 | -50.0% | 0.30% | -23.1% |
Q2 2018 | $421,000 | +31.6% | 5,012 | -3.7% | 0.39% | +15.2% |
Q1 2018 | $320,000 | +5.3% | 5,204 | 0.0% | 0.34% | +7.7% |
Q4 2017 | $304,000 | -39.6% | 5,204 | -39.9% | 0.31% | -49.5% |
Q3 2017 | $503,000 | – | 8,666 | – | 0.62% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
CM Management, LLC | 45,000 | $668,000 | 0.50% |
EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |